Edition:
India

Lipocine Inc (LPCN.OQ)

LPCN.OQ on NASDAQ Stock Exchange Capital Market

1.27USD
22 Jun 2018
Change (% chg)

$-0.05 (-3.79%)
Prev Close
$1.32
Open
$1.31
Day's High
$1.32
Day's Low
$1.27
Volume
60,316
Avg. Vol
51,366
52-wk High
$5.32
52-wk Low
$1.03

Latest Key Developments (Source: Significant Developments)

Lipocine Announces Q1 Loss Per Share $0.13
Monday, 7 May 2018 

May 7 (Reuters) - Lipocine Inc ::LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2018.Q1 LOSS PER SHARE $0.13.Q1 EARNINGS PER SHARE VIEW $-0.21 -- THOMSON REUTERS I/B/E/S.AS OF MARCH 31, 2018, COMPANY HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $27.8 MILLION.  Full Article

Lipocine Says ‍As Of December 31, 2017 Co Had Cash, Cash Equivalents And Marketable Securities Of $21.5 Mln​
Monday, 12 Mar 2018 

March 12 (Reuters) - Lipocine Inc ::LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017.LIPOCINE INC - ‍AS OF DECEMBER 31, 2017, LIPOCINE HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $21.5 MILLION​.  Full Article

Lipocine Says FDA's BRUDAC Voted 6 In Favor & 13 Against Benefit/Risk Profile Of Tlando
Thursday, 11 Jan 2018 

Jan 10 (Reuters) - Lipocine Inc ::LIPOCINE - FDA'S BRUDAC VOTED 6 IN FAVOR & 13 AGAINST BENEFIT/RISK PROFILE OF CO'S ORAL TESTOSTERONE PRODUCT CANDIDATE FOR TRT IN ADULT MALES, TLANDO.LIPOCINE INC SAYS ‍FDA DECISION ON TLANDO NDA IS ANTICIPATED BY ASSIGNED PDUFA GOAL DATE OF MAY 8, 2018 - SEC FILING ​.LIPOCINE INC - CONTINUE TO BELIEVE EFFICACY AND SAFETY RESULTS FROM CLINICAL STUDIES WITH TLANDO CONSISTENT WITH OTHER FDA APPROVED TRT PRODUCTS.  Full Article

Lipocine Says On Jan 5, Co, Unit, Silicon Valley Bank Entered Into Loan, Security Agreement
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Lipocine Inc ::LIPOCINE INC SAYS ON JAN 5, CO, UNIT, SILICON VALLEY BANK ("SVB") ENTERED INTO A LOAN AND SECURITY AGREEMENT -SEC FILING.LIPOCINE SAYS PURSUANT TO AGREEMENT SVB HAS AGREED TO LEND CO $10.0 MILLION; LOAN MATURES ON DEC 1, 2021.  Full Article

Lipocine says ‍FDA assigned a new prescription drug user fee act goal date of May 8, 2018 for Tlando​
Friday, 17 Nov 2017 

Nov 17 (Reuters) - Lipocine Inc :U.S. FDA extends review for Tlando™; advisory committee meeting date of January 10, 2018 remains unchanged.Lipocine Inc - ‍FDA has assigned a new prescription drug user fee act goal date of May 8, 2018 for Tlando​.  Full Article

Lipocine Inc Q3 loss per share $0.22
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Lipocine Inc :Lipocine announces financial and operational results for the third quarter and nine months ended September 30, 2017.Q3 loss per share $0.22.Q3 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.  Full Article

Lipocine Inc files for mixed shelf of up to $150 million
Saturday, 14 Oct 2017 

Oct 13 (Reuters) - Lipocine Inc :Lipocine Inc files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article

Clarus Therapeutics provides update on patent infringement lawsuit
Thursday, 13 Oct 2016 

Lipocine Inc : Clarus therapeutics provides update on patent infringement lawsuit against Lipocine’s oral product for testosterone replacement therapy . Clarus therapeutics - patent infringement lawsuit against Lipocine, Inc. that had been filed in U.S. District court in Delaware has been dismissed .Clarus Therapeutics - court found there was not immediate reason to hear case given Lipocine's failure to receive FDA market approval for LPCN-1021.  Full Article

Lipocine Q2 loss per share $0.32
Tuesday, 9 Aug 2016 

Lipocine Inc : Q2 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S . Lipocine announces financial and operational results for the second quarter of 2016 .Q2 loss per share $0.32.  Full Article

Lipocine expects to incur about $370,000 of cash expenditures
Tuesday, 19 Jul 2016 

Lipocine Inc : Estimates it will incur approximately $370,000 of cash expenditures . Company began notifying affected employees on July 18, 2016 . Lipocine Inc says annual costs savings of $1.7 million are expected upon completion of restructuring plan . Approved a restructuring and reduction in force plan of eight employees, constituting approximately 33% of company's workforce . Expects to recognize most of these restructuring charges during three months ended September 30, 2016 .Annual costs savings of $1.7 million are expected upon completion of restructuring plan - SEC filing.  Full Article

BRIEF-Lipocine Receives Complete Response Letter For Tlando From U.S. FDA

* LIPOCINE RECEIVES COMPLETE RESPONSE LETTER FOR TLANDO FROM U.S. FOOD AND DRUG ADMINISTRATION